To Amend The Arkansas Pharmacy Benefits Manager Licensure Act; And To Create The Pharmacy Services Administrative Organization Act.
SB593 amends Arkansas’s Pharmacy Benefits Manager Licensure Act and creates a new Pharmacy Services Administrative Organization Act. The bill defines and regulates pharmacy services administrative organizations (PSAOs), which are entities that help community pharmacies negotiate and administer contracts with pharmacy benefit managers (PBMs) and other healthcare payors. It also adds definitions for concepts such as a PBM national contract to pharmacies and PSAO contracting, tying those terms to statewide regulation.
The bill requires PSAOs operating in Arkansas to register with the State Insurance Department, pay an initial registration fee of $250, and comply with application and renewal requirements set by the Insurance Commissioner. It also imposes annual reporting and disclosure obligations, including reporting the number of in-state pharmacy contracts, identifying PBMs with and without agreements, and disclosing ownership or control relationships involving wholesalers or retail pharmacies. PSAOs must notify the department of material ownership changes within five business days. The bill further requires PBMs to offer Arkansas-specific amendments to PSAO arrangements by January 1, 2026, and it sets contract transparency rules requiring PSAOs to provide pharmacies copies of contracts, amendments, payment schedules, or reimbursement rates within specified timeframes.
SB593 would affect Arkansas insurance and pharmacy regulation by placing PSAOs under the oversight of the Insurance Commissioner and making their operations subject to registration, reporting, disclosure, and enforcement provisions. It also authorizes the commissioner to review PSAO agreements during active investigations, treat certain information as proprietary and confidential, and adopt rules to administer the new subchapter. The bill gives the commissioner authority to revoke, suspend, or place a PSAO registration on probation after notice and hearing.
The overall sentiment in the available record is neutral to supportive in structure, but there is no committee transcript or recorded vote history provided to show debate, amendments, or opposition. Based on the bill text alone, the measure appears aimed at increasing transparency and oversight in pharmacy contracting rather than changing patient benefits directly. Because no discussion or voting data is included, there is no documented public sentiment to report beyond the bill’s regulatory intent.
Notable potential points of contention are the new compliance burdens on PBMs and PSAOs, the requirement for Arkansas-specific contract amendments, and the disclosure of ownership/control relationships. The bill also allows the Insurance Commissioner to review agreements during investigations and to receive complaints about “take it or leave it” contract terms, which may be viewed by industry stakeholders as expanding regulatory scrutiny. At the same time, pharmacies and pharmacists may support the bill’s contract-access and reimbursement transparency provisions.
SB593 would expand Arkansas law by creating a new regulatory framework for pharmacy services administrative organizations within the Insurance Department’s oversight and by amending existing PBM licensure definitions. It would impose registration, fee, reporting, disclosure, contract-transparency, and enforcement requirements on PSAOs, while also requiring PBMs to provide Arkansas-compliant contract amendments and allowing the Insurance Commissioner to investigate and sanction noncompliant PSAOs. The bill would directly affect PSAOs, PBMs, pharmacies, pharmacists, and other healthcare payors involved in pharmacy network contracting.
No committee transcript or vote record is available, so there is no documented debate or recorded legislative sentiment to summarize. From the bill text, the measure appears to be framed as a consumer- and pharmacy-protective regulatory bill focused on transparency and oversight, which suggests likely support from community pharmacy interests and possible concern from PBMs and PSAOs over added regulation and contract restrictions.
The main areas of potential contention are the bill’s new registration and reporting requirements, the obligation for PBMs to create Arkansas-specific amendments, and the disclosure of ownership and control ties to wholesalers or retail pharmacies. PBMs and PSAOs may object to the administrative burden, confidentiality issues, and the commissioner’s authority to review agreements and enforce compliance, while pharmacies and pharmacists are likely to favor the bill’s access to contract terms, reimbursement information, and complaint process for allegedly noncompliant contract language.